Virios Therapeutics Inc (NASDAQ:VIRI) does about 1.08M shares in volume on a normal day but saw 824751 shares change hands in the recent trading day. The company now has a market cap of 5.61M USD. Its current market price is $0.20, marking an increase of 2.95% compared to the previous close of $0.20. The 52 week high reached by this stock is $1.08 whilst the lowest price level in 52 weeks is $0.16.
Virios Therapeutics Inc (VIRI) has a 20-day trading average at $0.1937 and the current price is -81.22% off the 52-week high compared with 29.87% distance from its 52-week low. The 50-day simple moving average of the closing price is $0.2077 and its 200-day simple moving average is $0.3702. If we look at the stock’s price movements over the week, volatility stands at 9.64%, which increases to 11.28% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 53.77 to suggest the stock is neutral.
The consensus objective for the share price is $1.00, suggesting that the stock has a potential upside of 80.0% over the period.
The current price level is 4.71%, -3.12%, and -45.65% away from its SMA20, SMA50, and SMA200 respectively, with the VIRI price moving above the 50-day SMA on current market day. Virios Therapeutics Inc (VIRI) stock is up 15.21% over the week and 6.98% over the past month. Its price is -64.83% year-to-date and -80.56% over the past year.
The stock last released its quarterly earnings report for quarter ended 6/30/2024, with the company’s earnings per share (EPS) of -0.06 above consensus estimates by 0.03. The company’s next earnings report forecasts estimating quarterly EPS at -0.05 and -0.22 for whole year.
To reach the target analysts have set, the stock logically needs to grow 80.0 percent from here.
Outstanding shares total 27.76M with insiders holding 6.74% of the shares and institutional holders owning 6.12% of the company’s common stock. The company has a return on investment of -149.22% and return on equity of -119.56%. The beta has a value of 1.59. Price to book ratio is 1.79.
